Dana-Farber initiates CV Care program for prostate cancer patients on ADT
The CV Care program aims to assess and manage cardiovascular risk factors in prostate cancer patients undergoing androgen deprivation therapy.
Asset / Drug
Drug and asset intelligence for Dana-Farber with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.